Showing results (411-420 of 447) with videos related to
Sort By:
Pageof 45
European Journal of Cancer (Oxford, England : 1990)|September 17, 2024
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trialAlexander Mm Eggermont, Michal Kicinski, Christian U Blank, et al.The New England Journal of Medicine|April 17, 2018
Adjuvant Pembrolizumab versus Placebo in Resected Stage III MelanomaAlexander M M Eggermont, Christian U Blank, Mario Mandala, et al.Lancet (London, England)|June 4, 2015
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.The New England Journal of Medicine|September 12, 2017
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaJedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.JAMA Oncology|January 3, 2020
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical TrialAlexander M M Eggermont, Michal Kicinski, Christian U Blank, et al.European Journal of Cancer (Oxford, England : 1990)|October 22, 2021
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanomaAlexander Mm Eggermont, Andrey Meshcheryakov, Victoria Atkinson, et al.Genome Biology|August 28, 2014
Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolutionRosalie Fisher, Stuart Horswell, Andrew Rowan, et al.Cancer|July 17, 2020
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trialRobert J Motzer, Bernard Escudier, Saby George, et al.NEJM Evidence|February 6, 2024
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III MelanomaAlexander M M Eggermont, Michal Kicinski, Christian U Blank, et al.Journal of Translational Medicine|October 29, 2014
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013Paolo A Ascierto, Antonio M Grimaldi, Ana Carrizosa Anderson, et al.Pageof 45